RO5454291

CAS No. ——

RO5454291( RO 5454291 )

Catalog No. M16939 CAS No. ——

RO5258638 is a small molecule inhibitor of CDK5-p25 protein-protein interaction with IC50 of 1.39 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    RO5454291
  • Note
    Research use only, not for human use.
  • Brief Description
    RO5258638 is a small molecule inhibitor of CDK5-p25 protein-protein interaction with IC50 of 1.39 uM.
  • Description
    RO5258638 is a small molecule inhibitor of CDK5-p25 protein-protein interaction with IC50 of 1.39 uM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    RO 5454291
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    357.458
  • Molecular Formula
    C19H27N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCC(C)(C)C(N(C1)CC2=C1C(NC3=NC(OC)=CC=C3)=NN2)=O
  • Chemical Name
    1-(3-((6-methoxypyridin-2-yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(1H)-yl)-2,2-dimethylbutan-1-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bellón-Echeverría I, et al. Sci Rep. 2018 Mar 23;8(1):5083.
molnova catalog
related products
  • Purvalanol B

    A potent, cell-permeable, selective inhibitor of CDK with IC50s of 6, 6, 9, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, and cdk5-p35 respectively.

  • Olomoucine

    A potent, ATP-competetive CDKs inhibitor with IC50 of 7, 7, 7, 3 uM for Cdc2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, and Cdk/p35 kinase; also inhibits ERK1/MAP kinase (IC50=25 uM).

  • BML-259

    BML-259 is an inhibitor of CDK5 and CDK2 with IC50s of 64 and 98 nM, respectively. BML-259 can be used in studies about the treatment of cancer and neurodegenerative diseases.